FOLR1 CAR T-cells
Phase 1Cell therapy
FOLR1 CAR T-cells is one of 8 biologic programs targeting Recurrent Childhood Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Recurrent Childhood Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 1
Cytosar
TevaPhase 1
Trexall
Jazz PharmaceuticalsPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Wellcovorin
EEastern Cooperative Oncology Group
Phase 1
Hydrocortisone Sodium Succinate
NNational Cancer Institute (NCI)
Phase 1
Rytelo
GGeron Corporation
Phase 1
FOLR1 CAR T-cells
FFred Hutchinson Cancer Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FOLR1 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- FFred Hutchinson Cancer Center